Literature DB >> 4439871

Disappearance of phenazone from plasma in patients with obstructive jaundice.

J Elfström, S Lindgren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4439871     DOI： 10.1007/BF00560360

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  14 in total

1.  Liver functino studies during and after complete extra-hepatic biliary obstruction in the dog.

Authors:  K F ARONSEN
Journal:  Acta Chir Scand Suppl       Date:  1961

2.  Bile drainage after choledochostomy in man, with some observations on biliary fistula.

Authors:  F F RUNDLE; M H CASS; B ROBSON; M MIDDLETON
Journal:  Surgery       Date:  1955-06       Impact factor: 3.982

3.  The use of antipyrine in the measurement of total body water in man.

Authors:  R SOBERMAN; B B BRODIE
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

4.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

5.  Factors influencing drug elimination in man.

Authors:  L Dettli; P Spring
Journal:  Farmaco Sci       Date:  1968-09

6.  The experimental obstructive jaundice and liver microsomal enzymes in rats.

Authors:  E H Kaltiala
Journal:  Ann Chir Gynaecol Fenn       Date:  1971

7.  Effect of bilirubin on drug conjugations in children.

Authors:  G Levy; I J Ertel
Journal:  Pediatrics       Date:  1971-05       Impact factor: 7.124

8.  Interindividual differences in drug oxidation: clinical importance.

Authors:  F Sjöqvist; C von Bahr
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

9.  On the conjugation and formation of bile acids in the human liver. VI. On the conjugation of cholic acid -2414C in human liver homogenates in various diseases with special reference to patients with jaundice; bile acids and steroids 66.

Authors:  P H EKDAHL
Journal:  Acta Chir Scand       Date:  1958

10.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059
View more
  9 in total

1.  Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

Authors:  C J van Boxtel; J T Wilson; S Lindgren; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

Review 2.  Drug metabolism in liver disease.

Authors:  L F Prescott; J A Forrest; K K Adjepon-Yamoah; N D Finlayson
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1975

3.  Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice.

Authors:  G A McPherson; I S Benjamin; A R Boobis; M J Brodie; C Hampden; L H Blumgart
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

Review 4.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

5.  Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction.

Authors:  J Wójcicki; T Sulikowski; M Wójcicki; M Droździk; B Gawrońska-Szklarz; B Barcew-Wiszniewska; J Skowron; L Rózewicka
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

6.  Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis.

Authors:  J P Miguet; D Vuitton; J P Deschamps; H Allemand; C Joanne; P Bechtel; P Carayon
Journal:  Dig Dis Sci       Date:  1981-08       Impact factor: 3.199

7.  Pharmacokinetics of lidocaine and its major metabolite- monoethylglycinexylidide (MEGX) in rabbits with experimental common bile duct obstruction.

Authors:  J Wójcicki; T Sulikowski; M Wójcicki; M Droździk; B Gawrońska-Szklarz; B Barcew-Wiszniewska; J Skowron; L Rózewicka; U Gołdyn
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

8.  Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents.

Authors:  E Richter; D D Breimer; W Zilly
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

9.  Antipyrine clearance in patients with Gilbert's syndrome.

Authors:  T Ishizaki; K Chiba; T Sasaki
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.